City of Hope has so many breakthroughs in cancer, diabetes and HIV/AIDS - and so many stories - that we've tailored our blog, Breakthroughs, to provide something for every reader. Whether the breakthroughs are about medical research, treatment advances or personal triumphs, they're all connected.
January 12, 2018 | Letisia Marquez
Larry Kwak, M.D., Ph.D., received a grant to support his work with mantle cell lymphoma from the Leukemia & Lymphoma Society, the world’s largest voluntary health organization dedicated to fighting blood cancer.
December 11, 2017 | Katie Neith
Researchers led by Alex Herrera, M.D. have found that a combination of two immunotherapy drugs may be a more tolerable way for patients to fight the disease before a transplant.
November 28, 2017 | Denise Heady
For the 46th year in a row, City of Hope will participate in the Tournament of Roses Parade. This year, 10 patients will welcome 2018 atop City of Hope’s Rose Parade float. Here, we meet float rider Chad Bible, a 21-year-old college student and Division 1 baseball player at San Diego State University.
October 20, 2017 | Denise Heady
Ever since Bliley's mother passed away from Hodgkin lymphoma when he was 8 years old, he knew he wanted to help other patients like his mom. He just wasn’t sure how. When he turned 18, he finally found a way – by donating platelets to cancer patients who desperately needed transfusions to live.
October 18, 2017 | City of Hope
City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR T therapy for adult patients who have not responded to or who have relapsed after at least two other kinds of treatment.
July 12, 2017 | Samantha Bonar
Monica Curiel was 19 years old, a freshman in college, when diagnosed. Now a survivor, her book, Stella's Picture Day, for pediatric cancer patients, was published in May 2016.
June 29, 2017 | Katie Neith
Clinical trial results in positive outcomes for patients with relapsed or treatment-resistant disease. Hodgkin lymphoma is typically considered to be one of the most curable forms of cancer, but some with the disease relapse or find that their cancer is resistant to treatment. For patients like this, a fully human monoclonal antibody called avelumab has shown promising results in a phase 1 clinical trial for safety and efficacy.
June 5, 2017 | Michael Easterling
As an oncology nurse, Christine Magnus Moore, R.N., B.S.N., has cared for patients going through the most challenging circumstances one can imagine. But she didn’t fully comprehend the courage of these cancer patients until she became one herself.
Load MoreBack To Top